NASDAQ:CERSCerus Stock Price, Forecast & News

Cerus' stock was trading at $4.76 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CERS stock has increased by 46.8% and is now trading at $6.99.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus.

Cerus is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) announced its earnings results on Tuesday, August, 4th. The biotechnology company reported ($0.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The biotechnology company had revenue of $21.50 million for the quarter, compared to analyst estimates of $21.50 million. Cerus had a negative return on equity of 76.83% and a negative net margin of 83.78%.
View Cerus' earnings history.

Cerus updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $112.8 million.

4 brokers have issued 1 year target prices for Cerus' shares. Their forecasts range from $6.50 to $9.00. On average, they anticipate Cerus' share price to reach $7.63 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts' price targets for Cerus.

Media coverage about CERS stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cerus earned a daily sentiment score of 0.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Cerus.

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Opko Health (OPK), Immunomedics (IMMU), Advanced Micro Devices (AMD), Pfizer (PFE) and ACADIA Pharmaceuticals (ACAD).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (6.54%), Vanguard Group Inc. (5.31%), Paradigm Capital Management Inc. NY (0.92%), Peregrine Capital Management LLC (0.88%), Raymond James & Associates (0.73%) and Silvercrest Asset Management Group LLC (0.58%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including Pier Capital LLC, Silvercrest Asset Management Group LLC, Peregrine Capital Management LLC, FMR LLC, Paradigm Capital Management Inc. NY, Lesa Sroufe & Co, Bank of America Corp DE, and CFM Wealth Partners LLC. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

CERS stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., UBS Group AG, Marshall Wace North America L.P., EAM Investors LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Cubist Systematic Strategies LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $6.99.

Cerus has a market capitalization of $1.16 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]